Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Jones, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
165 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Imvs
Adelaide, South Australia, Australia
- Western Hospital
Footscray, Victoria, Australia
- Royal Melbourne Hospital
Melbourne, Victoria, Australia
- Flinders Medical Centre
Bedford Park, Australia
- St. Vincent Hospital
Fitzroy, Australia
- Nepean Hospital
Kingswood, NSW, Australia
- Calvary Mater Hospital
Waratah, Australia
- Westmead Hospital Australia
Westmead, Australia
- Universitaetsklinik Innsbruck
Innsbruck, Austria
- Medical University of Vienna Internalmedicine 1, Hematology
Vienna, Austria
- Hopital Erasme
Brussels, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Hopital de Jolimont
Haine-Saint-Paul, Belgium
- Az Groeninge
Kortrijk, Belgium
- Uz Leuven
Leuven, Belgium
- Chu Mont -Godinne
Yvoir, Belgium
- Monte Tabor - Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
- Biocancer - Centro de Pesquisa E Tratamento Do Câncer S/a
Belo Horizonte, Minas Gerais, Brazil
- Hospital Nossa Senhora Da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
- Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
- Fundacao Pio Xii - Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
- Hospital Universitario de Brasilia
Brasílía, Brazil
- Hospital Erasto Gaertner
Curitiba, Brazil
- Pro Onco Centro de Tratamento Oncologico
Londrina, Brazil
- Hospital Israelita Albert Einstein
Morumbi, Brazil
- Instituto Estadual Arthur de Siqueira Cavalcanti - Hemorio
Rio de Janeiro, Brazil
- Instituto Nacional de Cancer - Inca
Rio de Janeiro, Brazil
- Centro de Estudos E Pesquisas de Hematologia E Oncologia Da Faculdade de Medicina Do Abc
Santo André, Brazil
- Fundação Antonio Prudente - Ac Camargo Câncer Center
São Paulo, Brazil
- Instituto de Ensino E Pesquisa Sao Lucas
São Paulo, Brazil
- Mhat Georgi Stranski Plevenhematology Clinic
Pleven, Bulgaria
- University Hospital Sveti Georgi Hematology Clinic
Plovdiv, Bulgaria
- Military Medical Academy
Sofia, Bulgaria
- National Specialized Hospital for Active Treatment of Hematology Diseases
Sofia, Bulgaria
- University Hospital Sveta Marina
Varna, Bulgaria
- Regional Health Authority B-Saint John Regional Hospital
Saint John, New Brunswick, Canada
- General Hospital, Eastern Health
St. John's, Newfoundland and Labrador, Canada
- Hospital Charles Lemoyne
Greenfield Park, Quebec, Canada
- Sacre-Couer Hospital
Montreal, Quebec, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Oct 2009
- Primary completion
- 31 Mar 2014
- Completion
- 9 May 2018
- Last update posted
- 9 Jul 2019
- Registered enrollment
- 450
- Registry id
- NCT00910910
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.